Investigational drug · Phase 3
Dazodalibep
Also called: VIB 4920, MEDI 4920, AMG 611
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Sjögren's Syndrome (SS), Sjögren's Syndrome, Sjogren's Syndrome.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
5
Any phase or sponsor naming "Dazodalibep"
First trial start
2024
Jan 24, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Dazodalibep", any sponsor or status.
Conditions studied
As listed on its trial records.
- Sjögren's Syndrome (SS)
- Sjögren's Syndrome
- Sjogren's Syndrome
Approved drugs for the same conditions: Immunology and inflammation · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "Dazodalibep" as an intervention, largest first.
- A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)Pivotal-lookingRecruiting
AmgenAmgen (AMGN)
NCT06747949 · 844 participants (planned) · Start Feb 25, 2025 · Primary completion Dec 11, 2029
Drug: Dazodalibep · For: Sjögren's Syndrome
Sites: Avondale, Arizona; Flagstaff, Arizona; Gilbert, Arizona · 174 sites in all
- A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease ActivityPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT06104124 · 651 participants · Start Jan 24, 2024 · Primary completion Jul 23, 2026
Drug: Dazodalibep; Placebo · For: Sjogren's Syndrome
Sites: Avondale, Arizona; Chandler, Arizona; Flagstaff, Arizona · 206 sites in all
- A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom StatePivotal-lookingActive, not recruiting
AmgenAmgen (AMGN)
NCT06245408 · 434 participants · Start Apr 8, 2024 · Primary completion Oct 22, 2026
Drug: Dazodalibep; Placebo · For: Sjögren's Syndrome (SS)
Sites: Avondale, Arizona; Chandler, Arizona; Flagstaff, Arizona · 194 sites in all
- A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's SyndromePivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT04129164 · 183 participants · Start Dec 9, 2019 · Primary completion Sep 1, 2022
Drug: VIB4920; Placebo · For: Sjögren's Syndrome
Sites: Fullerton, California; Upland, California; Lawrenceville, Georgia · 62 sites in all
- A Study to Evaluate the Safety and Efficacy of VIB4920 in Participants With Rheumatoid ArthritisCompleted
AmgenAmgen (AMGN)
NCT04163991 · 78 participants · Start Dec 9, 2019 · Primary completion Dec 28, 2021
Drug: VIB4920; Placebo · For: Rheumatoid Arthritis
Sites: Anniston, Alabama; Sun City, Arizona; Upland, California · 25 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Humanistic Burden of Sjögren's Disease: A Systematic Review of Treatment Efficacy on Health-Related Quality of Life.
Akpek EK, Adamson E, Shea L, et al. · Rheumatol Ther 2026
- Immunosuppressive and immunomodulatory therapies in Sjögren's disease: current landscape and future perspectives.
Yazisiz V · Expert Opin Pharmacother 2026
- Efficacy and safety of pharmacological treatment for Sjögren's disease: a network meta-analysis.
Yang M, Lu Y, Wang S, et al. · Z Rheumatol 2026
- Re-engineering CD154 blockade for transplantation: Fc-free design to separate thrombotic risk from therapeutic function.
Hwang S, Chun M, Chung J · Clin Transplant Res 2026
- [Pathophysiological aspects of primary Sjögren's disease : From epithelial activation to systemic autoimmunity].
Ritter J, Dörner T · Z Rheumatol 2026
- Bridging the Gap in Sjögren's Disease: A Comprehensive Review of Unmet Needs, Diagnostic Challenges, and Emerging Therapeutic Strategies.
Aung T · Cureus 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Amgen.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.